Rationale for the utilization of interleukin-4, an immune-recognition induced cytokine, in cancer immunotherapy.
Interleukin-2 use for advanced cancer treatment has demonstrated that cytokines are of interest not only in the field of immunology but also in oncology. Interleukin-2 is only one member of the ever-growing family of immune recognition-induced lymphokines. Interleukin-4, a cytokine with pleiotropic effects, shares some common properties with interleukin-2. Availability of recombinant interleukin-4 has led to a better knowledge of this cytokine's functions, and also makes clinical trials possible. This brief review discusses the in vitro and in vivo data that support a potential use of interleukin-4 in cancer immunotherapy.
Costello
R
R
Unité INSERM U119 Cancérologie et Thérapeutique Expérimental, Marseille, France.
Lipcey
C
C
Olive
D
D
D000818:Animals; D006801:Humans; D007167:Immunotherapy; D015847:Interleukin-4 / Q000276:immunology / Q000627:therapeutic use*; D009369:Neoplasms / Q000628:therapy*
D015847:Interleukin-4